In a recent clinical study, USANA Health Sciences, Inc. evaluated the efficacy and tolerance of its Celavive Resurfacing Serum. Participants of the study included 33 women with mild to moderate skin concerns who reported seeing statistically significant improvements in the appearance of their skin in two weeks.
The Celavive Resurfacing Serum was formulated with a blend of alpha and beta hydroxy acids, niacinamide, peptides and bakuchiol (a naturally-derived retinol). After a 12-week study, participants reported a reduction in the appearance of fine lines and pores and an improvement in their skin’s clarity and radiance.
“We are very pleased with the results of the Resurfacing Serum clinical study, and hope this will resonate well with our customer base,” said Dr. Kathryn Armstrong, USANA Chief Scientific Officer. “Clinical studies are the best way to show the efficacy of a product, and the outcome of this study demonstrates the high quality of our Resurfacing Serum and USANA as a whole. As a company dedicated to science and quality, USANA invests a significant amount in research and development so it is imperative we provide our customers with the most effective products possible.”
